Effects of protease inhibitors on postischemic recovery of the heart

Cardiovascular Drugs and Therapy

Volumn 11, Issue 4, 1997, Pages 547-556

  Shibata, Toshihiko ^a   Yamamoto, Futnio ^b   Suehiro, Shigefumi ^a   Kinoshita, Hiroaki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Gabexate mesilate; Myocardial ischemia; Nafamostat mesilate; NCO 700; Protease inhibitor; Urinastatin

Indexed keywords

BIS[3 [3 METHYL 1 [4 (2,3,4 TRIMETHOXYBENZYL) 1 PIPERAZINYLCARBONYL]BUTYLCARBAMOYL]OXIRANE 2 CARBOXYLIC ACID ETHYL ESTER] HYDROGEN SULFATE; CARDIOPLEGIC AGENT; GABEXATE MESILATE; NAFAMSTAT MESILATE; PROTEINASE; PROTEINASE INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; THIOL PROTEINASE; ULINASTATIN;

ANIMAL TISSUE; ARTICLE; CYTOSOL; DOSE RESPONSE; ENZYME ACTIVATION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; ISOLATED HEART; LYSOSOME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CREATINE KINASE; GABEXATE; GLYCOPROTEINS; GUANIDINES; HEART; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PIPERAZINES; PROTEASE INHIBITORS; RATS; RATS, WISTAR;

EID: 0030827787     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007723417775     Document Type: Article

References (18)

1. K. Lysosomal alterations in ischemic myocardium: Result or cause of damage? J Mol Cell Cardiol, 1978;10:595-603.
2. Barrack J, et al. Aprotinin improves myocardial recovery after ischemia and reperfusion. J Thorac Cardiovasc Surg 1994;108:109-118.
3. Tanaka H, Okamura T, Suzuki T, et al. Protective effect of protease inhibitor "Aprotinin" on acute ischemic myocardium. Rinaho Kyobu Geka 1984;4:644-649.
4. Sunamori M, Sultan I, Suzuki A. Effect of aprotinin to improve myocardial viability in myocardial preservation followed by reperfusion. Ann Thorac Surg 1991;52:971-978.
5. Hjelms E, Waldorff S, Steiness E, Bergsten O. Aprotinin does not add protective effect to cold cardiopelgia during coronary artery surgery. Scand J Thor Cardiovasc 1986;20; 11-13.
6. Shibata T, Yamamoto F, Ohashi T, et al. The effects of protease inhibitor upon the ischemia-reperfusion injury. J. Jpn Assoc, Thorac Surg 1992;40:33-38
7. Hearse DJ. Models and markers for the investigation of myocardial tissue damage. In Hearse DJ, Braimbridge MV, Jynge P (eds). Protection of the ischemic myocardium: Cardioplegia. New York: Raven Press, 1981:50-92.
8. Langendorff O. Untersuchungen am uberlebenden Saugethierherezen. Pflügers Arch 1895;61:291-332.
9. Yamamoto F, Yamamoto H, Yoshida S, et al. The effects of several pharmacologie agents upon postischemic recovery. Cardiovasc Drugs Ther 1991;8:301-308.
10. Tbyo-oka T, Kamishiro K, Kara K, Nakamura N, Kitahara M, Masaki T. Suppression of myocardial protein degradation by the protease inhibitor bis[ethyl(2R,3R)-3-[(S)methyl-l-[4-(2,3,4-tri-methoxy-phenyl-methyl)piperazine- l-y lcarbonyl] butyl-carbonyl]oxiran-2-carboxylate]sulfate under hypoxia. Arzneimittelforshung 1986;36:190-193.
11. Yoshitomi H. Experimental studies on protective effects of urinastatin on "reperfusion injury" using isolated working rat heart model. J. Nagoya City Med Center 1993;44:143-155
12. Gerhardt W. Methods of Enzymatic Analysis III, 3rd ed. Weinheim: Verlag Chemie, 1983:510-518.
13. Ichihara K, Hayase N, Chiba K, Parvez H, Yasushi A. Effect of NCO-700, an inhibitor of protease, on lysosomal rupture in the ischemia myocardium. J Pkarm Sci 1991;80:252-254.
14. Tbyo-oka T, Kamishiro T, Masaki M, Masaki T. Reduction of experimentally produced acute myocardial infarction size by a new synthetic inhibitor, NCO-700, against calcium-activated neutral protease. Jpn Heart J 1982;23:829-834.
15. Gabrielescu E, Butur G, Nicolau N, Ciobanu A, Nutu O. Histochemical investigation of myocardial proteases in heart anoxia, under protection with cardioplegic solution and protease inhibitors. Rom J Morphol Embryol 1989; 26:101-110.
16. Tbyo-oka T, Kamishiro Y, Gotoh Y, Fumio H, Masaki T, Hosoda S. Temporary salvage of ischemia myocardium by the protease inhibitor bis[ethyl (2R,3R)-3-[(S)-methyl-l-[4(2,3,4-tri-methoxy-phenyl-methyl) piperazine-l-ylcarbonyl ]butyl-carbonyl]oxiran-2-carboxylate] sulfate. Arzneimittelforshung 1986;36:671-675.
17. Yoshizaki A, Aoki M, Hosaka H, et al. Changes of cardiac metabolism in ischemie myocardium treated with urinastatin. Shinkin no Kozo to Taisha 1987;10:203-215.
18. Shimai S, Tanaka T, Kiuchi K, et al. Reduction of the extent of ischemic myocardial injury by ulinastatin in the early stage of acute myocardial infarction. Sinzo 1989;21: 1077-1081.